CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling
Luomeng Qian, Ping Chen, Bo Wang, Qing Zhang, Yuan Guo, Jie Cui, Ran Ding, Hongkai Zhang, Sihe Zhang · 2026
Read CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling by Luomeng Qian, Ping Chen, Bo Wang, Qing Zhang, Yuan Guo, Jie Cui, Ran Ding, Hongkai Zhang, Sihe Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13500725.txt.
Description
Luomeng Qian leads a nine-author team reporting a 2026 study of why liver cancer tumours stop responding to the drug sorafenib. Sorafenib blocks blood vessel growth, which leaves tumours short of oxygen. The team found that low oxygen makes hepatocellular carcinoma cells release more migrasomes, large vesicles shed by migrating cells, and that these vesicles carry the protein CD147 on their surface. Such vesicles were linked to tumours that resist the drug.
The vesicles enter other cancer cells by macropinocytosis, a gulping form of uptake that depends on a receptor called LPAR6. Once inside, the CD147-bearing vesicles switch on a PI3K/AKT/TWIST1 signalling chain. That chain pushes cancer cells to form their own vessel-like channels, a process called vasculogenic mimicry, which feeds the tumour and sustains resistance. Blocking both the vesicle uptake and the channel formation made sorafenib kill cancer cells more effectively.
Catalog record
| CREATOR | Luomeng Qian, Ping Chen, Bo Wang, Qing Zhang, Yuan Guo, Jie Cui, Ran Ding, Hongkai Zhang, Sihe Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52752 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |